Skip to menu Skip to content Skip to footer

2006

Journal Article

The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

Keane, Colm, Gibbs, Simon, Seymour, John F., Mills, Anthony K ., Grimmett, Karen, Van Kuilenberg, Rosita, Russell, Saal, Gill, Devinder, Prince, H. Miles, Marlton, Paula and Mollee, Peter (2006). The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 24 (3), 159-163. doi: 10.1002/hon.784

The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

2006

Journal Article

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Lane, Steven W., Crawford, Julie, Kenealy, Melita, Cull, Gavin, Seymour, John F., Prince, H. Miles, Marlton, Paula, Gill, Devinder ‌ and Mollee, Peter‌ N. (2006). Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 47 (9), 1813-1817. doi: 10.1080/10428190600632832

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

2006

Journal Article

The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function

Seshadri, T., Hourigan, M. J., Wolf, M., Mollee, P. N. and Seymour, J. F. (2006). The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leukemia Research, 30 (4), 483-485. doi: 10.1016/j.leukres.2005.08.014

The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function

2006

Journal Article

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

Kuruvilla, John, Song, Kevin, Mollee, Peter, Panzarella, Tony, McCrae, Jan, Nagy, Tracy, Crump, Michael and Keating, Armand (2006). A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology, 11 (1), 25-29. doi: 10.1080/10245330500276592

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

2006

Journal Article

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

Gandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P. J., Prince, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. (2006). Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12 (2), 460-464. doi: 10.1158/1078-0432.CCR-05-2008

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

2006

Conference Publication

Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases

Tate, J.R., Mollee, P., Carter, A. and Gill, D. (2006). Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases. 58th Annual Meeting of the American Association of Clinical Chemistry, Chicago, IL, United States, 23-27 July 2006. Washington, DC, United States: American Association for Clinical Chemistry.

Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases

2006

Conference Publication

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).

Lane, SW, Saal, R, Negus, S, Mollee, P, Mather, M, Gill, D, Mills, AK, Bird, RJ, Hourigan, MJ, Jones, M and Marlton, P (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando Fl, Dec 09-12, 2006. WASHINGTON: AMER SOC HEMATOLOGY.

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).

2006

Journal Article

Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system

Dimeski, Goce, Mollee, Peter and Carter, Andrew (2006). Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system. Clinical Chemistry, 52 (1), 155-156. doi: 10.1373/clinchem.2005.054981

Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system

2006

Conference Publication

Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).

Lane, SW, Saal, R, Mollee, P, Grigg, A, Taylor, K, Seymour, JF, Kennedy, G, Williams, B, Jones, M, Grimmett, K, Griffiths, V, Gill, D, Hourigan, M and Marlton, P (2006). Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology.

Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).

2006

Journal Article

Hereditary fibrinogen A alpha-chain amyloidosis

Lane, S. W., Goodman, H. J., Francis, L., Bofinger, A. M. and Mollee, P. N. (2006). Hereditary fibrinogen A alpha-chain amyloidosis. Pathology, 38 (4), 380-382. doi: 10.1080/00313020600820823

Hereditary fibrinogen A alpha-chain amyloidosis

2005

Journal Article

Increased Lipid Concentration Is Associated with Increased Hemolysis

Dimeski, Goce, Mollee, Peter and Carter, Andrew (2005). Increased Lipid Concentration Is Associated with Increased Hemolysis. Clinical Chemistry, 51 (12), 2425-2425. doi: 10.1373/clinchem.2005.058644

Increased Lipid Concentration Is Associated with Increased Hemolysis

2005

Conference Publication

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

Mollee, Peter, Tate, Jill, Dimeski, Goce and Gill, Devinder (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.5077.5077

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

2005

Conference Publication

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

Lane, Steven W., Mollee, Peter N., Bird, Robert, Porceddu, Sandro and Gill, Devinder (2005). Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL). 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.4993.4993

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

2005

Journal Article

Role of VAD in the initial treatment of multiple myeloma

Lane, Steven W., Gill, Devinder, Mollee, Peter N. and Rajkumar, S. Vincent (2005). Role of VAD in the initial treatment of multiple myeloma. Blood, 106 (10), 3674-3675. doi: 10.1182/blood-2005-07-2610

Role of VAD in the initial treatment of multiple myeloma

2005

Journal Article

The reporting of serum protein electrophoresis to clinicians

Tate, Jillian R., Mollee, Peter and Gill, Devinder (2005). The reporting of serum protein electrophoresis to clinicians. Clinica Chimica Acta, 358 (1-2), 204-205. doi: 10.1016/j.cccn.2005.04.010

The reporting of serum protein electrophoresis to clinicians

2005

Journal Article

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

Song, Kevin W., Mollee, Peter N., Hogge, Donna E., Gupta, Vikas, Bernett, Michael J., Forrest, Donna L., Lavoie, Julye C., Nevill, Thmas J., Nantel, Stephen H., Shepherd, John D., Smith, Clay A., Sutherland, Heather J., Toze, Cynthia L., Crump, Michael and Keating, Armand (2005). Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia and Lymphoma, 46 (4), 525-531. doi: 10.1080/10428190400025112

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

2005

Journal Article

Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?

Rifkind, Joshua, Mollee, Peter, Messner, Hans and Lipton, Jeffrey (2005). Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?. Leukemia & Lymphoma, 46 (2), 217-223. doi: 10.1080/10428190400015022

Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?

2005

Journal Article

Serum free light chains for monitoring multiple myeloma

Tate, J., Mollee, P. and Gill, D. (2005). Serum free light chains for monitoring multiple myeloma. British Journal of Haematology, 128 (3), 405-406. doi: 10.1111/j.1365-2141.2004.05338.x

Serum free light chains for monitoring multiple myeloma

2005

Conference Publication

Accelerated delivery of Rituximab is safe on an out-patient basis.

Middleton, HJ, Mollee, P, Bird, R, Mills, AK, Marlton, P and Gill, D (2005). Accelerated delivery of Rituximab is safe on an out-patient basis.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 10-13, 2005. WASHINGTON: AMER SOC HEMATOLOGY.

Accelerated delivery of Rituximab is safe on an out-patient basis.

2005

Journal Article

Stem cell transplantation for mantle cell lymphoma: if, when and how?

Kiss, T. L., Mollee, P., Lazarus, H. M. and Lipton, J. H. (2005). Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplantation, 36 (8), 655-661. doi: 10.1038/sj.bmt.1705080

Stem cell transplantation for mantle cell lymphoma: if, when and how?